Metabolic evaluation: who, when and how often by De Coninck, Vincent et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Metabolic evaluation: who, when and how often
De Coninck, Vincent; Keller, Etienne Xavier; Traxer, Olivier
Abstract: PURPOSE OF REVIEW To summarize recommendations of the guidelines of the American
Urological Association and European Association of Urology, and our opinion on which urinary tract
stone disease patients should be metabolically evaluated at which moment and how often. RECENT
FINDINGS A standard metabolic evaluation should be performed in all stone formers to prevent recurrent
disease. This includes a medical and lifestyle history, physical examination, basic urine and blood analysis,
radiological examination and stone analysis. The latter should already be performed during surgery,
especially when only a couple of fragments are sent for analysis. Supplementary, performing a 24-h
urine analysis should be supported in all patients to understand the lithogenic process that will guide the
according follow-up. When risk factors are found, an extended individualized metabolic evaluation should
be performed to exclude underlying metabolic diseases and to start stone-specific recurrence prevention.
SUMMARY Urologists should be trained in perioperative stone characterization, because it contains
information of urinary environment at the times of stone formation and growth. The extensiveness and
frequency of metabolic work-up and follow-up of stone formers should be tailored to the type of stone,
severity of the disease, patient’s comorbidities and medications.
DOI: https://doi.org/10.1097/MOU.0000000000000562
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-159405
Journal Article
Published Version
Originally published at:
De Coninck, Vincent; Keller, Etienne Xavier; Traxer, Olivier (2019). Metabolic evaluation: who, when
and how often. Current Opinion in Urology, 29(1):52-64.
DOI: https://doi.org/10.1097/MOU.0000000000000562
D
ow
nloaded
from
https://journals.lw
w
.com
/co-urology
by
B
hD
M
f5eP
H
K
av1zE
oum
1tQ
fN
4a+kJLhE
ZgbsIH
o4X
M
i0hC
yw
C
X
1A
W
nY
Q
p/IlQ
rH
D
3K
irptP
A
LrnD
i+TL0TbiLtN
hR
Y
G
30LM
gO
hE
Y
ax8qR
Jm
s=
on
12/07/2018
Downloadedfromhttps://journals.lww.com/co-urologybyBhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3KirptPALrnDi+TL0TbiLtNhRYG30LMgOhEYax8qRJms=on12/07/2018
 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
 CURRENTOPINION Metabolic evaluation: who, when and how often
Vincent De Conincka,b,c, Etienne Xavier Kellera,b,d, and Olivier Traxera,b
Purpose of review
To summarize recommendations of the guidelines of the American Urological Association and European
Association of Urology, and our opinion on which urinary tract stone disease patients should be
metabolically evaluated at which moment and how often.
Recent findings
A standard metabolic evaluation should be performed in all stone formers to prevent recurrent disease. This
includes a medical and lifestyle history, physical examination, basic urine and blood analysis, radiological
examination and stone analysis. The latter should already be performed during surgery, especially when
only a couple of fragments are sent for analysis. Supplementary, performing a 24-h urine analysis should
be supported in all patients to understand the lithogenic process that will guide the according follow-up.
When risk factors are found, an extended individualized metabolic evaluation should be performed to
exclude underlying metabolic diseases and to start stone-specific recurrence prevention.
Summary
Urologists should be trained in perioperative stone characterization, because it contains information of
urinary environment at the times of stone formation and growth. The extensiveness and frequency of
metabolic work-up and follow-up of stone formers should be tailored to the type of stone, severity of the
disease, patient’s comorbidities and medications.
Keywords
metabolic evaluation, prevention, recurrence, stone analysis, urinary stone disease
INTRODUCTION
The worldwide prevalence of kidney stones has been
increasing over the past decades, with a triplication
in several countries since the First World War [1–3].
This increase is mainly caused by a modification in
dietary habits with a decreased intake of fibres and
alkali-rich food (such as vegetables and fruits), and
an increased intake of refined sugar, fat, animal
proteins and sodium [4,5]. Other causes of stone
formation include congenital or acquired disorders
causing metabolic disorders. To discover these
underlying causes and diseases in stone formers, it
is of utmost importance to perform a metabolic
evaluation to tailor an adequate therapy [6].
There is, however, a lack of consensus which
patients should be considered for an in-depth met-
abolic investigation. It also remains unclear when,
how and how often patients should be evaluated.
We aim to answer these questions based on the
current guidelines of the American Urological Asso-
ciation (AUA) and European Association of Urology
(EAU), and our opinion.
STANDARD EVALUATION
The AUA and EAU guidelines state that all first-time
stone formers should be evaluated with a medical
and dietary history, a basic biochemical work-up of
urine and blood, and a radiological evaluation. A
reliable stone analysis by infrared spectroscopy or X-
ray diffraction should be performed in all first-time
stone formers following the EAU guidelines and at
least once following the AUA guidelines [7,8].
History and physical examination
Following AUA and EAU guidelines, an anamnesis
targeting personal and medical history, diet and
medication, and physical examination should be
systematically performed in all stone formers to
understand the lithogenic process and to interpret
the urinalysis [7,9].
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Lifestyle factors and medical conditions may
predispose to stone disease and may make some
additional examinations redundant. Insufficient
diuresis is a frequent risk factor that might be par-
ticularly pronounced in patients with low fluid
intake or high extrarenal fluid losses (e.g. athletes,
teachers, drivers or people living or working in hot
environments) [10,11,12
&
]. Further, it involves ques-
tioning about age of first stone diagnosis [13], medi-
cal history (e.g. urinary tract infections, diarrhoea,
inflammatory bowel disease, cystic fibrosis, chronic
pancreatitis, gout, diabetes, renal tubular acidosis
type 1, hyperparathyroidism, sarcoidosis, Sjo¨gren’s
syndrome, bone disease) [14,15] and surgical history
(e.g. fracture, bariatric surgery, bowel resection)
[16–18], and also medication causing metabolic
disorders leading to stone formation (e.g. protease
inhibitors, carbonic anhydrase inhibitors, supple-
ments of vitamins or calcium) or inducing stones
(e.g. amoxicillin, atazanavir, ceftriaxone, ciproflox-
acin, sulfamethoxazole) [19
&
]. Each of these pathol-
ogies or medications is associated with specific types
of stones and should ring a bell to prevent or
decrease stone recurrence (Table 1).
Dietary habits are related to kidney stone forma-
tion as well [21]. These habits can be evaluated with
a food intake registration of 3 days. Another option
is using a food frequency questionnaire to obtain
information of frequency and portion size over
1 week [22]. This survey evaluates the intake of fluid
(amount and type of beverages), calcium, sodium,
animal proteins, sugar, purines and oxalate. In gen-
eral, high fluid intake decreases the risk of recurrent
nephrolithiasis by reducing crystallization [23]. A
rich calcium diet can lead to hypercalciuria, whereas
a low calcium intake increases the intestinal
absorption and renal excretion of oxalate [24].
Foods high in sodium decrease the renal re-absorp-
tion of calcium, phosphate, oxalate and uric acid
[25]. High-protein foods stimulate the endogenous
oxalate and uric acid synthesis, and induce an acid
overload that decreases renal re-absorption of cal-
cium and excretion of citrate. This metabolic acido-
sis also decreases urinary pH, which facilitates
crystallization of uric acid [26,27
&
]. Hyperglycaemia
results in reduced ammoniumbuffer excretion and a
low urine pH, leading to uric acid stone formation
[28]. In practice, reducing soft drink intake lowers
the risk of urolithiasis formation in patients with
high baseline soft drink consumption [29]. In sum-
mary, patients with recurrent calciumoxalate stones
and hypercalciuria should be specifically screened
for any excessive protein and/or salt intake, and also
excessive calcium intake [24,30,31]. In case of
hyperuricosuria or disorders linked to the uric acid
synthetic pathway, excessive purine and fructose
intake should be excluded [32].
During physical examination, obesity, hyperten-
sion and scars related to surgery should not be over-
looked [33,34]. All patients should be measured and
weighed, because overweight shows clear alterations
in metabolic urinary profiles that are associated with
increased overall risk of stone formation [35].
Basic urine and blood analysis
Each patient with urolithiasis needs a succinct urine
and blood analysis to identify biochemical causes of
stone formation [36]. Both AUA and EAU guidelines
recommend dipstick and microscopic evaluation to
assess urine pH, indicators of infection and to iden-
tify crystals pathognomonic of stone type [7,9].
Following EAU guidelines, blood analysis
includes at least creatinine, uric acid, (ionized) cal-
cium, sodium, potassium, blood cell count and C-
reactive protein [8]. In contrast to AUA guidelines,
they do not recommend systematically analyzing
chloride and bicarbonate [7]. They rather recom-
mend measuring serum bicarbonate when urinary
pH levels are constantly above 5.8. When bicarbon-
ate is low, renal tubular acidosis may be identified,
leading to calciumphosphate stone formation. High
urine pH in combination with the presence of ure-
ase-producing bacteria substantiates the suspicion
of struvite stones [8]. Surprisingly, glycaemia is not
mentioned either in the EAU or in the AUA guide-
lines, even though urolithiasis may occur as a first
presentation of diabetes mellitus [37].
Medical imaging examinations
The EAU and AUA guidelines both recommend
imaging studies to quantify stone burden [7,8]. This
KEY POINTS
 All first-time stone formers should be evaluated with a
medical and dietary history, a basic biochemical work-
up of urine and blood (including glycaemia), a
radiological evaluation and stone analysis.
 Stone characterization should already be performed
during surgical treatment.
 A basic 24-h and a fresh early morning urinalysis
should be considered in all stone formers.
 An extensive patient-specific evaluation should be
individually determined.
 The frequency of metabolic work-up and follow-up of
stone formers should be tailored to the type of stone,
severity of the disease, patient comorbidities
and medications.
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can be performed with ultrasound, plain abdominal
radiograph and (low-dose) computed tomography
(CT) that disclose information about stone charac-
teristics, including the number, size, morphology
and radiopacity.
Preoperatively, stone composition can be esti-
mated based on radiological imaging. On plain
abdominal radiograph, weddellite stones are char-
acterized by blur contours and intermediate density,
whereas cystine stones have blunt contours and a
low density. Whewellite and brushite stones have a
high density with smooth and speculated contours,
respectively. Stones mainly composed of uric acid,
ammonium urate, xanthine or 2.8-dihydroxyade-
nine are radiolucent on plain abdominal imaging.
Drug stones and protein matrix stones are also
radiolucent on CT [38].
With CT imaging, Hounsfield unit density can
be used to characterize differences in radiodensities
among urinary stones and can be helpful in plan-
ning alternative treatment for patients with a likeli-
hood of a poor outcome from shockwave lithotripsy
[39–42]. Dual-energy CT is able to differentiate uric
acid, cystine, struvite and mixed stones from other
types of stones [43,44].
In our opinion, every stone former should have
at least once a CT urography to reflect the anatomy
of the urinary tract and to reveal even small or subtle
collecting system abnormalities [45]. Nephrocalci-
nosis and anatomical anomalies favouring stones
like medullary sponge kidney, calyceal diverticula
and horseshoe kidney can be differentiated with this
examination [46–49].
Stone examination
Following EAU guidelines, every and each stone or
fragments of a stone should be send for determina-
tion of composition by X-ray diffraction or infrared
spectroscopy, because stone composition is a cor-
nerstone for further diagnostic and management
decisions [9,50–52]. In contrast, AUA guidelines
state that a stone analysis should be performed at
least once when a stone is available, because it may
help direct preventive measures [7].
Stone characterization should already be per-
formed during endoscopic surgical treatment,
because there is a variability in the reporting of
stones among laboratories [53]. Surface characteri-
zation is based on colour, size, pattern and aspect of
crystals, and also on morphological particularities
(e.g. papillary umbilication with a Randall’s plaque).
During lithotripsy, internal features like concentric,
radial, compact or loose structure, and the organi-
zation of alternating layers can help determining
the stone type (Table 1 and Fig. 1). Other important
marks for understanding the lithogenic process are
the localization of the stone (e.g. diverticulum,
bladder), its mounting surface and its metabolic
activity (e.g. greyish layer of crystals covering
the stone surface indicating recent episode of
FIGURE 1. Stone classification from type Ia to VI (surface
and section), according to Daudon et al.
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hyperoxaluria) [20]. Considering all these parame-
ters will help in the early detection of certain dis-
eases, especially when blood and urine analyses are
normal [54].
Calcium oxalate monohydrate or whewellite
stones (type I) are associated with hyperoxaluria.
This can be caused by extensive oxalate intake (e.g.
cacao, dark chocolate, pepper, spinach, rhubarb, tea
leaves, star fruit, sorrel, beets) or inadequately low
fluid intake, inflammatory bowel diseases, short
bowel syndrome or genetic disorders. Noticing sub-
type Ic stones should raise a red flag because they are
pathognomonic for primary hyperoxaluria andmay
lead to renal failure as early as infancy. A high
proportion of calcium oxalate stones are a mixture
of whewellite and weddellite (type II) stones. The
latter are associated with hypercalciuria. Hyperuri-
cosuria can provoke type III stones. They are sub-
divided in uric acid stones (type IIIa and IIIb) and
urate stones (type IIIc and IIId). Patients diagnosed
with type IIId stones should be suspected for chronic
diarrhoea with phosphorus deficiency and malnu-
trition. Type IVa carbonate apatite (carbapatite)
stones are frequently found in patients with chronic
urinary tract infections. Other causes include
renal tubular acidosis (type IVa2) or primary
FIGURE 1. (Continued ).
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hyperparathyroidism (type IVd, or type IIa or IIb
with IVa1). When smelling sulfide and seeing white
bubbles during lithotripsy, diagnosis of cystinuria
(type V) is made peroperatively [20].
Stones contain information of urinary environ-
ment at the times of formation and growth. Because
less than 10% of stones are pure, it is important to
identify the composition during lithotripsy when
FIGURE 1. (Continued ).
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only a couple of fragments are sent for analysis.
Frequent stone associations are Ia or Ibþ IIa or IIb
in case of intermittent hyperoxaluria and hyper-
calciuria, IIa or IIbþ IVa1 in case of absorptive
or resorptive (e.g. primary hyperparathyroidism,
immobilization, hyperthyroidism) hypercalciuria,
and Iaþ IIIb in case of metabolic syndrome and/or
type 2 diabetes with hyperoxaluria [20].
SUPPLEMENTARY EVALUATION
The aim of performing a 24-h urine collection and a
fresh early morning urine sample is to detect
changes in the urine that may be associated with
stone formation. It is widely discussed whether
these examinations should be part of a basic assess-
ment or not [51]. Following AUA and EAU guide-
lines, clinicians should only perform 24-h urine
collections in a selective group of stone formers
[7,9]. In our opinion, a basic 24-h and a fresh early
morning urinalysis should be considered in all stone
formers for the reasons exposed hereafter.
Twenty-four-hour and fresh early morning
urine collection
Following AUA guidelines, clinicians should per-
form one or two 24-h urine collections in high-risk
or interested first-time stone formers and recurrent
stone formers. High-risk stone formers are defined as
those with a family history of stone disease, malab-
sorptive intestinal disease or intestinal resection,
recurrent urinary tract infections, obesity ormedical
conditions predisposing to stones (e.g. gout, diabe-
tes mellitus type 2, renal tubular acidosis type 1,
primary hyperparathyroidism, sarcoidosis) and
patients with a solitary kidney. Recurrent stone
formers include patients with repeated stone epi-
sodes and those with multiple stones at initial pre-
sentation. Urine metabolic testing should consist at
minimum of total volume, pH, creatinine, calcium,
sodium, potassium, uric acid, oxalate and citrate.
Testing potassium, urea and cystine is only recom-
mended in specific cases [7].
Following EAU guidelines, only high-risk
patients require a specific metabolic evaluation with
two consecutive 24-h urine collections. This risk
stratification is not only based on disease severity
but also on stone types [9]. For calcium oxalate
stones, urinalysis requires measurement of urine
volume, pH, specific gravity, calcium, sodium, mag-
nesium, uric acid, oxalate and citrate. For calcium
phosphate stones, it includes volume, pH, specific
gravity, calcium, phosphate and citrate. For uric acid
and ammonium urate stones, urine volume, pH,
specific gravity and uric acid level are recom-
mended. For cystine stones, urine volume, pH, spe-
cific gravity and cystine should bemeasured. In case
of struvite stones, only repeated urine pH measure-
ments are recommended. The EAU guidelines state
that this metabolic work-up should be ideally per-
formed on a self-determined diet in an ambulatory
FIGURE 1. (Continued ).
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setting in a patient who is stone-free or at least
3 weeks after a urological intervention [8].
In our opinion, a basic 24-h urinalysis and a
fresh early morning urine sample should be consid-
ered in all motivated stone formers to understand
the lithogenic processes, underlying diseases, to
propose individualized pharmacological and diet
interventions, and to monitor them during fol-
low-up [6,9,52,55–58]. Initially, this basic 24-h uri-
nalysis should only include six parameters: total
volume, creatinine (validation of adequate 24-h
urine sampling), calcium, sodium (daily sodium
intake), urea (daily protein intake) and uric acid
(fructose and purine metabolism). Early morning
urine should include pH and specific gravity. pH
should be measured with a portable pH meter or a
laboratory pHmeter because they are more accurate
compared to reagent strips readings [59
&
]. These
tests should be performed a couple of weeks after
surgery or stone expulsion when the patient is on a
self-determined diet under normal daily conditions.
Performing a second collection as part of the initial
evaluationmay be of interest, because variations are
intrinsic to patients’ diet and activities.
For most first-time stone formers with type Ia,
Ib, IIa, IIb, IIIa or IIIb stones, this basic 24-h and a
fresh early morning urinalysis provide sufficient
information to guide preventivemeasures and treat-
ment. Other stone type formers require an extensive
evaluation in most cases.
FIGURE 1. (Continued ).
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EXTENSIVE EVALUATION
An extensive patient-specific evaluation should be
individually determined. It is based on patient’s
medical history (e.g. early onset of stone formation,
stone recurrence, diseases or environmental factors
associated with stone formation, genetically deter-
mined stone formation), physical examination (e.g.
obesity, arterial hypertension), urine and blood
analysis (e.g. underlying metabolic disorder), medi-
cal imaging examinations (e.g. multiple stones, ana-
tomical abnormalities associated with stone
formation, solitary kidney, nephrocalcinosis, med-
ullary sponge kidney), stone analysis (e.g. drug-
induced stone formation) and in case of stones of
unknown composition.
Extensive urine and blood analysis
Depending on the results of abovementioned inves-
tigations, additional haematological parameters that
should be analysed may be bicarbonate (e.g. meta-
bolic acidosis), phosphate (e.g. renal phosphatewast-
ing), magnesium (e.g. mutations in CLDN16 or
CLDN16), PTH (e.g. hypercalcaemia and hypercal-
ciuria), calcidiol and calcitriol (e.g. hypercalcaemia
and hypercalciuria). When hypercalciuria cannot be
FIGURE 1. (Continued ).
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explained by dietary habits, a calcium load test with
or without a bone densitometry to exclude osteope-
nia should be performed [60].
Twenty-four-hour urinalysis can be extended
with oxalate (e.g. primary and enteric hyperoxalu-
ria, nephrocalcinosis), citrate (e.g. renal tubular aci-
dosis, medullary sponge kidney), phosphate (e.g.
renal phosphate wasting, estimating protein and
diary product intake) and cystine (cystinuria).
The study of crystalluria is a cheap and valuable
tool for diagnosis and monitoring of acquired and
congenital disorders associated with urolithiasis. It
reflects different lithogenic factors (e.g. uric acids,
urates, calcium oxalates, calcium phosphates), it
may orient to rare diseases (e.g. deficiency of ade-
nine phosphoribosyltransferase) or drug-related
stones (e.g. amoxicillin, atazanavir, ceftriaxone, cip-
rofloxacin, sulfamethoxazole), and reflects the
activity of stone diseases and the response to thera-
peutic measures (e.g. primary hyperoxaluria, cystin-
uria) [61]. Crystalluria examinations should be
performed on fresh first-voided morning urine sam-
ples, because urine produced during the night is
usually the most concentrated and therefore carries
the highest risk of supersaturation and crystal for-
mation [62].
FOLLOW-UP
After the initiation of dietary measures, medication
or treatment of underlying diseases, the initial fol-
low-up of stone patients should be individualized
depending on the type of stones, stone growth or
new stone formation, therapeutic tools and
patient’s motivation [51]. Depending on the under-
lying lithogenic factors, this can be performed using
well selected above mentioned examinations. Mon-
itoring these specific parameters allows the assess-
ment of patient’s compliance, dietary habits and
response to medical therapy. This should be per-
formed with a 24-h urine collection to assess
response to dietary and/or medical therapy within
2–3 months after starting pharmacological preven-
tion of stone recurrence following EAU guidelines
and within 6months following AUA guidelines. The
latter guidelines state that patients on pharmaco-
logical therapy should undergo earlier period blood
testing to assess for adverse events [7,8].
After the initial follow-up and once urinary
parameters have been normalized, a 24-h urine
collection should be performed annually or more
frequently depending on stone activity following
the AUA guidelines or, if necessary, following the
EAU guidelines.
Repeatingmedical imaging (either by ultrasound,
plain abdominal imaging or non-contrast-enhanced
low-dose CT) to assess for stone growth or new stone
formation should be basedon stone activity. In case of
stone recurrence, stone analysis should be repeated.
Follow-upmaybediscontinuedwhenpatients remain
stone-free for an extended period [7,8].
CONCLUSION
The AUA and EAU guidelines differ about how,
when and how often a metabolic evaluation should
be performed, because there is little published evi-
dence on this issue. While stone analysis is a corner-
stone for further diagnostic and management
decisions according to the EAU guidelines, it is only
a tool to direct preventive measures following the
AUA guidelines. The latter guidelines are also less
selective for a 24-h urine analysis. In contrast, the
EAU guidelines recommend a stricter follow-up what
we applaud. In our opinion, performing perioperative
stone recognition and 24-h urine analysis should
be supported to understand the lithogenic process
which will guide patients during follow-up.
In conclusion, stratification of stone formers
should be based on medical and lifestyle history,
physical examination, basic urine and blood analy-
sis, radiological examination and per and postoper-
ative stone analysis. The latter is of utmost
importance because it contains the metabolic his-
tory of the patient and defines the recurrence risk. In
absence of risk factors, preventive individualized
measures including appropriate drink intake, bal-
anced diet and lifestyle advice are sufficient. In case
of risk factors, an extended individualizedmetabolic
evaluation should be performed to exclude under-
lying diseases and to start stone-specific recurrence
prevention. Thereafter, the frequency of metabolic
work-up and follow-up of stone formers should be
tailored to the type of stone, severity of the disease,
patient’s comorbidities and medications.
Acknowledgements
Our special thanks go to Michel Daudon (Laboratoire des
Lithiases, Service des Explorations Fonctionnelles Multi-
disciplinaires, AP-HP, Hoˆpital Tenon, Paris, France) for
providing the pictures and proofreading this article.
Vincent De Coninck and Etienne Xavier Keller contrib-
uted equally to the writing of this article.
Financial support and sponsorship
Professor Olivier Traxer is a consultant for Coloplast,
Rocamed, Olympus, EMS and Boston Scientific. Dr Vin-
cent De Coninck is supported by the EUSP scholarship
from the European Association of Urology and by a grant
from the Belgische Vereniging voor Urologie (BVU). Dr
Etienne Xavier Keller is supported by a Travel Grant from
Special commentary
62 www.co-urology.com Volume 29  Number 1  January 2019
 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
the University Hospital Zurich and by a grant from the
Kurt and Senta Herrmann Foundation.
Conflicts of interest
There are no conflicts of interest.
REFERENCES AND RECOMMENDED
READING
Papers of particular interest, published within the annual period of review, have
been highlighted as:
& of special interest
&& of outstanding interest
1. Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of
prevalence, incidence, and associated risk factors. Rev Urol 2010;
12:e86–96.
2. Robertson WG, Peacock M, Hodgkinson A. Dietary changes and the in-
cidence of urinary calculi in the U.K. between 1958 and 1976. J Chronic Dis
1979; 32:469–476.
3. Morgan MS, Pearle MS. Medical management of renal stones. Br Med J 2016;
352:i52.
4. Trinchieri A, Coppi F, Montanari E, et al. Increase in the prevalence of
symptomatic upper urinary tract stones during the last ten years. Eur Urol
2000; 37:23–25.
5. Robertson WG, Peacock M. The pattern of urinary stone disease in Leeds and
in the United Kingdom in relation to animal protein intake during the period.
Urol Int 1982; 37:394–399.
6. Kocvara R, Plasgura P, Petrik A, et al. A prospective study of nonmedical
prophylaxis after a first kidney stone. BJU Int 1999; 84:393–398.
7. Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management of kidney
stones: AUA guideline. J Urol 2014; 192:316–324.
8. Turk C, Neisius A, Petrik A, et al. EAU Guidelines on Urolithiasis (update
March 2018). https://uroweb.org/guideline/urolithiasis/. [Accessed 27
June 2018]
9. Skolarikos A, Straub M, Knoll T, et al. Metabolic evaluation and recurrence
prevention for urinary stone patients: EAU guidelines. Eur Urol 2015;
67:750–763.
10. Borghi L, Meschi T, Amato F, et al. Urinary volume, water and recurrences in
idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J
Urol 1996; 155:839–843.
11. Fink HA, Wilt TJ, Eidman KE, et al. Medical management to prevent recurrent
nephrolithiasis in adults: a systematic review for an American College of
Physicians Clinical Guideline. Ann Intern Med 2013; 158:535–543.
12.
&
Geraghty RM, Proietti S, Traxer O, et al. Worldwide impact of warmer seasons
on the incidence of renal colic and kidney stone disease: evidence from a
systematic review of literature. J Endourol 2017; 31:729–735.
Incidence of renal colic and kidney stone disease increases during warmer months.
13. Tasian GE, Copelovitch L. Evaluation and medical management of kidney
stones in children. J Urol 2014; 192:1329–1336.
14. Cameron MA, Sakhaee K. Uric acid nephrolithiasis. Urol Clin North Am 2007;
34:335–346.
15. Miano R, Germani S, Vespasiani G. Stones and urinary tract infections. Urol
Int 2007; 79(Suppl 1):32–36.
16. Letavernier E, Traxer O, Daudon M, et al. Determinants of osteopenia in male
renal-stone-disease patients with idiopathic hypercalciuria. Clin J Am Soc
Nephrol 2011; 6:1149–1154.
17. Upala S, Jaruvongvanich V, Sanguankeo A. Risk of nephrolithiasis, hyperox-
aluria, and calcium oxalate supersaturation increased after Roux-en-Y gastric
bypass surgery: a systematic review and meta-analysis. Surg Obes Relat Dis
2016; 12:1513–1521.
18. Sakhaee K, Poindexter J, Aguirre C. The effects of bariatric surgery on bone
and nephrolithiasis. Bone 2016; 84:1–8.
19.
&
Daudon M, Frochot V, Bazin D, et al. Drug-induced kidney stones and
crystalline nephropathy: pathophysiology, prevention and treatment. Drugs
2018; 78:163–201.
Drug-induced nephrolithiasis may result from crystallization of poorly soluble
molecules or from crystallization of metabolic compounds as a consequence of
the metabolic effects of the drugs.
20. Turney BW, Appleby PN, Reynard JM, et al. Diet and risk of kidney stones in
the Oxford cohort of the European Prospective Investigation into Cancer and
Nutrition (EPIC). Eur J Epidemiol 2014; 29:363–369.
21. Yasui T, Okada A, Hamamoto S, et al. The association between the incidence
of urolithiasis and nutrition based on Japanese National Health and Nutrition
Surveys. Urolithiasis 2013; 41:217–224.
22. Cheungpasitporn W, Rossetti S, Friend K, et al. Treatment effect, adherence,
and safety of high fluid intake for the prevention of incident and recurrent
kidney stones: a systematic review and meta-analysis. J Nephrol 2016;
29:211–219.
23. Borghi L, Schianchi T, Meschi T, et al. Comparison of two diets for the
prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med
2002; 346:77–84.
24. Nouvenne A, Meschi T, Prati B, et al. Effects of a low-salt diet on idiopathic
hypercalciuria in calcium-oxalate stone formers: a 3-mo randomized controlled
trial. Am J Clin Nutr 2010; 91:565–570.
25. Nouvenne A, Ticinesi A, Morelli I, et al. Fad diets and their effect on urinary
stone formation. Transl Androl Urol 2014; 3:303–312.
26. Robertson WG. Dietary recommendations and treatment of patients with
recurrent idiopathic calcium stone disease. Urolithiasis 2016; 44:9–26.
27.
&
Ticinesi A, Guerra A, Allegri F, et al. Determinants of calcium and oxalate
excretion in subjects with calcium nephrolithiasis: the role of metabolic
syndrome traits. J Nephrol 2018; 31:395–403.
Hypertension was the only metabolic syndrome trait with a significant positive
determinant of urinary calcium excretion in restrospective review on calcium stone
formers.
28. Fink HA, Akornor JW, Garimella PS, et al. Diet, fluid, or supplements for
secondary prevention of nephrolithiasis: a systematic review and meta-ana-
lysis of randomized trials. Eur Urol 2009; 56:72–80.
29. Siener R, Ebert D, Nicolay C, et al. Dietary risk factors for hyperoxaluria in
calcium oxalate stone formers. Kidney Int 2003; 63:1037–1043.
30. Goldfarb DS, Fischer ME, Keich Y, et al. A twin study of genetic and dietary
influences on nephrolithiasis: a report from the Vietnam Era Twin (VET)
Registry. Kidney Int 2005; 67:1053–1061.
31. Sakhaee K. Epidemiology and clinical pathophysiology of uric acid kidney
stones. J Nephrol 2014; 27:241–245.
32. Daudon M, Lacour B, Jungers P. Influence of body size on urinary stone
composition in men and women. Urol Res 2006; 34:193–199.
33. Madore F, Stampfer MJ, Rimm EB, et al. Nephrolithiasis and risk of hyperten-
sion. Am J Hypertens 1998; 11:46–53.
34. Shavit L, Ferraro PM, Johri N, et al. Effect of being overweight on urinary
metabolic risk factors for kidney stone formation. Nephrol Dial Transplant
2015; 30:607–613.
35. Turk C, Petrik A, Sarica K, et al. EAU guidelines on interventional treatment for
urolithiasis. Eur Urol 2016; 69:475–482.
36. Meydan N, Barutca S, Caliskan S, et al. Urinary stone disease in diabetes
mellitus. Scand J Urol Nephrol 2003; 37:64–70.
37. Matlaga BR, Shah OD, Assimos DG. Drug-induced urinary calculi. Rev Urol
2003; 5:227–231.
38. Motley G, Dalrymple N, Keesling C, et al. Hounsfield unit density in the
determination of urinary stone composition. Urology 2001; 58:170–173.
39. Gupta NP, Ansari MS, Kesarvani P, et al. Role of computed tomography with
no contrast medium enhancement in predicting the outcome of extracorporeal
shock wave lithotripsy for urinary calculi. BJU Int 2005; 95:1285–1288.
40. Tailly T, Larish Y, Nadeau B, et al. Combining mean and standard deviation of
hounsfield unit measurements from preoperative CT allows more accurate
prediction of urinary stone composition than mean Hounsfield units alone. J
Endourol 2016; 30:453–459.
41. Kawahara T, Miyamoto H, Ito H, et al. Predicting the mineral composition of
ureteral stone using noncontrast computed tomography. Urolithiasis 2016;
44:231–239.
42. Graser A, Johnson TR, Bader M, et al. Dual energy CT characterization of
urinary calculi: initial in vitro and clinical experience. Invest Radiol 2008;
43:112–119.
43. Spek A, Strittmatter F, Graser A, et al. Dual energy can accurately differentiate
uric acid-containing urinary calculi from calcium stones. World J Urol 2016;
34:1297–1302.
44. Caoili EM, Cohan RH, Korobkin M, et al. Urinary tract abnormalities: initial
experience with multidetector row CT urography. Radiology 2002;
222:353–360.
45. Koraishy FM, Ngo TT, Israel GM, et al. CT urography for the diagnosis of
medullary sponge kidney. Am J Nephrol 2014; 39:165–170.
46. Cheidde L, Ajzen SA, Tamer Langen CH, et al. A critical appraisal of the
radiological evaluation of nephrocalcinosis. Nephron Clin Pract 2007;
106:c119–124.
47. Stunell H, McNeill G, Browne RF, et al. The imaging appearances
of calyceal diverticula complicated by uroliathasis. Br J Radiol 2010;
83:888–894.
48. Glodny B, Petersen J, Hofmann KJ, et al. Kidney fusion anomalies revisited:
clinical and radiological analysis of 209 cases of crossed fused ectopia and
horseshoe kidney. BJU Int 2009; 103:224–235.
49. Pak CY, Poindexter JR, Adams-Huet B, et al. Predictive value of kidney stone
composition in the detection of metabolic abnormalities. Am J Med 2003;
115:26–32.
50. Kourambas J, Aslan P, Teh CL, et al. Role of stone analysis in metabolic
evaluation and medical treatment of nephrolithiasis. J Endourol 2001;
15:181–186.
51. Tiselius HG, Daudon M, Thomas K, et al. Metabolic work-up of patients with
urolithiasis: indications and diagnostic algorithm. Eur Urol Focus 2017;
3:62–71.
52. Krambeck AE, Khan NF, Jackson ME, et al. Inaccurate reporting of mineral
composition by commercial stone analysis laboratories: implications for
infection and metabolic stones. J Urol 2010; 184:1543–1549.
Metabolic evaluation De Coninck et al.
0963-0643 Copyright  2018 Wolters Kluwer Health, Inc. All rights reserved. www.co-urology.com 63
 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
53. Daudon M, Bader CA, Jungers P, et al. Urinary calculi: review of classification
methods and correlations with etiology. Scan Microsc 1993; 7:1081–1106.
54. Cloutier J, Villa L, Traxer O, et al. Kidney stone analysis: ‘give me your stone, I
will tell you who you are!’. World J Urol 2015; 33:157–169.
55. Hesse A, Brandle E, Wilbert D, et al. Study on the prevalence and incidence of
urolithiasis in Germany comparing the years 1979 vs. 2000. Eur Urol 2003;
44:709–713.
56. Straub M, Strohmaier WL, Berg W, et al. Diagnosis and metaphylaxis of stone
disease. Consensus concept of the National Working Committee on Stone
Disease for the upcoming German Urolithiasis Guideline. World J Urol 2005;
23:309–323.
57. Strohmaier WL. Course of calcium stone disease without treatment. What
can we expect? Eur Urol 2000; 37:339–344.
58. Torricelli FC, De S, Liu X, et al. Can 24-h urine stone risk profiles predict
urinary stone composition? J Endourol 2014; 28:735–738.
59.
&
De Coninck V, Keller EX, Rodriguez-Monsalve M, et al. Evaluation of a portable
urinary pH meter and reagent strips. J Endourol 2018; 32:647–652.
Patients should be involved in their care for stone management using accurate pH
meters instead of reagent strips.
60. Pak CY, Kaplan R, Bone H, et al. A simple test for the diagnosis of absorptive,
resorptive and renal hypercalciurias. N Engl J Med 1975; 292:497–500.
61. Daudon M, Frochot V. Crystalluria. Clin Chem Lab Med 2015; 53(Supple
2):s1479–1487.
62. Daudon M, Hennequin C, Boujelben G, et al. Serial crystalluria determination
and the risk of recurrence in calcium stone formers. Kidney Int 2005;
67:1934–1943.
Special commentary
64 www.co-urology.com Volume 29  Number 1  January 2019
